特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
920952

ネオアンチゲン癌ワクチンの世界市場:核酸/DNA/mRNAワクチン・RNAワクチン・ペプチドワクチン・樹状細胞ワクチン - 分析と予測 (2023-2030年)

Global Neoantigen Cancer Vaccine Market: Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape - Analysis and Forecast, 2023-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 255 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ネオアンチゲン癌ワクチンの世界市場:核酸/DNA/mRNAワクチン・RNAワクチン・ペプチドワクチン・樹状細胞ワクチン - 分析と予測 (2023-2030年)
出版日: 2019年12月23日
発行: BIS Research Inc.
ページ情報: 英文 255 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のネオアンチゲン癌ワクチン市場規模は、2030年までに18億2,610万米ドルに達すると予測されています。同市場は2023年から2030年にかけての予測期間中、34.69%のCAGR (年間複合成長率) で成長する見込みです。ネオアンチゲン癌ワクチン市場の成長は主に、癌有病率の増加、個別化医療の導入の高まり、およびR&Dを実施するための莫大な外部資金などです。しかし、臨床開発における個別化癌ワクチンの高額なコストなどは、市場の障壁となっています。

当レポートでは、世界のネオアンチゲン癌ワクチン市場について取り上げ、市場ダイナミクス、競合環境、各セグメント・地域別の市場、競合状況、および主要企業などについて詳細に分析しています。

920952_Figure 15.2_ Neoantigen Cancer Vaccine Market (by Region), $Million, 2023-2030

エグゼクティブサマリー

第1章 製品定義

第2章 調査範囲

第3章 調査手法

第4章 癌免疫療法におけるネオアンチゲンワクチン:概要

  • イントロダクション
  • 癌抗原
  • 癌ネオアンチゲンのターゲティング:オンコロジー (腫瘍学) におけるイノベーションの次の波?
  • ネオアンチゲン癌ワクチンの作用機序
  • ネオアンチゲン癌ワクチンの種類:製品タイプ別
  • ネオアンチゲン癌ワクチンの種類:ネオワクチンタイプ別:(生物学的プラットフォーム)
  • ネオアンチゲン癌ワクチンの種類:デリバリー戦略別
  • ネオアンチゲン向けソフトウェア予測
  • ネオアンチゲン癌ワクチンの制限事項
  • 将来の展望

第5章 法的要件・規制

  • ネオアンチゲン癌ワクチン向け規制経路の概要
  • 規制の課題
  • 製鋼する規制戦略

第6章 市場情勢

  • 成長シェア分析
  • FDAレビュー情勢
  • 特許情勢

第7章 市場ダイナミクス

  • 概要
  • 新興・現在の市場動向
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第8章 パイプライン情勢

  • 新しいネオアンチゲンワクチン
  • 治験ヒートマップ
  • パイプライン分析

第9章 競合情勢

  • 主な戦略・発展
  • 提携・金融の機会

第10章 世界のネオアンチゲン癌ワクチン市場:製品タイプ別

  • 個別化ネオアンチゲンワクチン
  • 市販ネオアンチゲンワクチン

第11章 世界のネオアンチゲン癌ワクチン市場:ネオワクチンのタイプ別

  • 核酸/DNA/mRNAワクチン
  • RNAワクチン
  • ペプチドワクチン
  • 樹状細胞ワクチン

第12章 世界のネオアンチゲン癌ワクチン市場:治療法別

  • 第一選択ネオワクチンレジメン
  • 第二選択ネオワクチンレジメン
  • その他

第13章 世界のネオアンチゲン癌ワクチン市場:治療タイプ別

  • 単独治療レジメン
  • 組み合わせレジメン

第14章 世界のネオアンチゲン癌ワクチン市場:治療専門分野別

  • 血液悪性腫瘍
  • 黒色腫
  • 乳癌
  • 消化管癌
  • 肺癌
  • 固形腫瘍
  • 尿路癌
  • 前立腺癌
  • 頭頚部癌
  • 婦人科癌
  • 脳癌

第15章 世界のネオアンチゲン癌ワクチン市場:地域別

  • 概要
  • 北米
  • カナダ
  • 欧州
  • アジア太平洋

第16章 企業プロファイル

  • Moderna Therapeutics
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca plc
  • Agenus
  • OSE Immunotherapeutics
  • Advaxis
  • Medigene
  • Neon Therapeutics
  • Genocea Biosciences
  • Immunovative Therapies
  • Gritstone Oncology
  • Nouscom
  • NantBioScience
  • Immunovaccine
  • BioLineRx

第17章 マイルストーン予測

図表

List of Tables

  • Table 4.1: Implications of PCV's
  • Table 4.2: Implications of Off-The-Shelf NCV
  • Table 4.3: Implications of DNA and RNA Vaccines
  • Table 4.4: Implications of Peptide Vaccines
  • Table 4.5: Implications of DC Vaccines
  • Table 4.6: Prediction Software Utilized by Various Companies
  • Table 6.1: Neoantigen Cancer vaccines Designation Landscape, by 2019
  • Table 6.2: Neoantigen Cancer Vaccines Patent Landscape, by 2019
  • Table 8.1: Key Neoantigen Vaccines in Clinical Development Phase 1, 2 & 3, by 2019
  • Table 8.2: Neoantigen Vaccines, by Therapy Type
  • Table 8.3: Neoantigen Vaccines, by Treatment Strategy
  • Table 8.4: Neoantigen Vaccines, by Line of Therapy
  • Table 8.5: Neoantigen Vaccines, by Route of Administration
  • Table 8.6: Neoantigen Vaccines, by Core Product Type (Licensed Products/ Technology only)
  • Table 8.7: Neoantigen Vaccines, by Payload
  • Table 9.1: Neoantigen Vaccines: Companies Status
  • Table 14.1: Neoantigen Vaccines for Hematological Malignancies
  • Table 14.2: Neoantigen Vaccines for Melanoma: Pipeline Products
  • Table 14.3: Neoantigen Vaccines for Breast Cancer: Pipeline Products
  • Table 14.4: Neoantigen Vaccines for GI Cancer: Pipeline Products
  • Table 14.5: Neoantigen Vaccines, by Lung Cancer: Pipeline Products
  • Table 14.6: Neoantigen Vaccines for Solid Tumors: Pipeline Products
  • Table 14.7: Neoantigen Vaccines for Urinary System Cancers: Pipeline Products
  • Table 14.8: Neoantigen Vaccines for Head and Neck Cancers: Pipeline Products
  • Table 14.9: Neoantigen Vaccines for Gynecologic Cancer: Pipeline Products
  • Table 14.10: Neoantigen Vaccines for Brain Cancer: Pipeline Products
  • Table 15.1: Key Developments
  • Table 15.2: Key Developments
  • Table 15.3: Key Developments
  • Table 15.4: Key Developments
  • Table 15.5: Key Developments
  • Table 15.6: Key Developments
  • Table 15.7: Key Developments
  • Table 15.8: Key Developments
  • Table 15.9: Key Developments
  • Table 17.1: Anticipated Milestones (Launch and Trials Outcomes Related to Neovaccines)

List of Figures

  • Figure 1: Impact Analysis of Market Drivers and Market Challenges on the Global Neoantigen Cancer Vaccine Market
  • Figure 2: Global Neoantigen Cancer Vaccine Market, By Product Type, 2023 vs. 2030 ($Million)
  • Figure 3: Global Neoantigen Cancer Vaccine Market, By Type of Neovaccine, 2023 vs. 2030 ($Million)
  • Figure 4: Global Neoantigen Cancer Vaccine Market, By Oncology Specialty, 2023 vs. 2030 ($Million)
  • Figure 5: Global Neoantigen Cancer Vaccine Market, By Line of Therapy, 2023 vs. 2030 ($Million)
  • Figure 6: Global Neoantigen Cancer Vaccine Market Snapshot
  • Figure 2.1: Global Neoantigen Cancer Vaccine Market Segmentation
  • Figure 2.2: Global Neoantigen Cancer Vaccine Existing Pipeline Segmentation
  • Figure 3.1: Global Neoantigen Cancer Vaccine Market Research Methodology
  • Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.3: Step by Step Approach
  • Figure 4.1: Step by Step Process for Neoantigen Vaccine Development
  • Figure 4.2: Type of Cancer Antigens
  • Figure 4.3: Specialized Therapies Segmentation in U.S.
  • Figure 4.4: NCV Mechanism of Action
  • Figure 4.5: Factors Affecting Neoantigen Prediction Process
  • Figure 4.6: Future Prospects
  • Figure 5.1: U.S. FDA Review Timeline
  • Figure 5.2: EMA Review Timeline
  • Figure 6.1: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Application), 2023-2030
  • Figure 6.2: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Product Type), 2023-2030
  • Figure 6.3: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Region), 2023-2030
  • Figure 6.4: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Line of Therapy), 2023-2030
  • Figure 6.5: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Type of Therapy), 2023-2030
  • Figure 6.6: Growth Share Matrix for Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), 2023-2030
  • Figure 6.7: Neoantigen Cancer Vaccines Designation Landscape
  • Figure 6.8: Share of Patents (by Ownership), 2016-2019
  • Figure 7.1: Number of Deaths due to Different Cancer Types, Million, 2018
  • Figure 7.2: Global Cancer Incidence in (Million), 2018
  • Figure 7.3: Neo-vaccines Funding and Expansion Activities Breakout (January 2016- September 2019)
  • Figure 7.4: Overall Financing Raised by Emerging Neo-Vaccines Companies (January 2016- September 2019)
  • Figure 7.5: Overview of Reimbursement Policies in Europe
  • Figure 7.6: Market Opportunities
  • Figure 8.1: Neoantigen Cancer Vaccines: Heat Map
  • Figure 8.2: Neoantigen Cancer Vaccines: Breakdown of Pipeline by Development Phase, 2019
  • Figure 8.3: Neoantigen Cancer Vaccines, by Type of Therapy
  • Figure 8.4: Neoantigen Cancer Vaccines, by Product Type
  • Figure 8.5: Neoantigen Cancer Vaccines, by Treatment Strategy
  • Figure 8.6: Neoantigen Cancer Vaccines, by Type of Neovaccine (Biological Platform)
  • Figure 8.7: Neoantigen Cancer Vaccine, by Delivery Approach
  • Figure 8.8: Neoantigen Cancer Vaccine, by Line of Therapy
  • Figure 8.9: Number of Neoantigen Cancer Vaccine, by Oncology Speciality
  • Figure 8.10: Neoantigen Cancer Vaccine, by Route of Administration
  • Figure 8.11: Neoantigen Cancer Vaccines, by Core Product Status
  • Figure 8.12: Neoantigen Cancer Vaccines, by Payload
  • Figure 9.1: Share of Key Developments and Strategies, January 2016-September 2019
  • Figure 9.2: Synergistic Activities Share (by Company), January 2016 - September 2019
  • Figure 9.3: Synergistic Activities Share (by Type), January 2016-September 2019
  • Figure 9.4: Funding and Expansions Share (by Company), January 2016-September 2019
  • Figure 9.5: Merger and Acquisitions Share (by Company), January 2016-September 2019
  • Figure 9.6: Neoantigen Cancer Vaccine Market, by Company Status
  • Figure 10.1: Global Neoantigen Cancer Vaccine Market (by Product Type), 2023 vs 2030
  • Figure 10.2: Personalized Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 10.3: Off-the-Shelf Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 11.1: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), 2023 vs 2030
  • Figure 11.2: Nucleic Acid-based Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 11.3: Peptide Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 11.4: Dendritic Cell-Based Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 12.1: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), 2023 vs 2030
  • Figure 12.2: First Line Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 12.3: Second Line Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 12.4: Later Lines Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 13.1: Global Neoantigen Cancer Vaccine Market (by Therapy Type), 2023 vs 2030
  • Figure 13.2: Neoantigen Cancer Vaccine Market (Mono Therapeutic Regimen), $Million, 2023-2030
  • Figure 13.3: Neoantigen Cancer Vaccine Market (Combination Therapeutic Regimens), $Million, 2023-2030
  • Figure 14.1: Number of Products Under Development as per Oncology Specialty, 2017-2019
  • Figure 14.2: Neoantigen Cancer Vaccine Market (Hematological Malignancies), $Million, 2023-2030
  • Figure 14.3: Neoantigen Cancer Vaccine Market (Melanoma), $Million, 2023-2030
  • Figure 14.4: Neoantigen Cancer Vaccine Market (Breast Cancer), $Million, 2023-2030
  • Figure 14.5: Neoantigen Cancer Vaccine Market (Gastrointestinal Cancer), $Million, 2023-2030
  • Figure 14.6: Neoantigen Cancer Vaccine Market (Lung Cancer), $Million, 2023-2030
  • Figure 14.7: Neoantigen Cancer Vaccine Market (Solid Tumors), $Million, 2023-2030
  • Figure 14.8: Neoantigen Cancer Vaccine Market (Urinary System Cancer), $Million, 2023-2030
  • Figure 14.9: Neoantigen Cancer Vaccine Market (Prostate Cancer), $Million, 2023-2030
  • Figure 14.10: Neoantigen Cancer Vaccine Market (Head and Neck Cancers), $Million, 2023-2030
  • Figure 14.11: Neoantigen Cancer Vaccine Market (Gynecologic Cancer), $Million, 2023-2030
  • Figure 14.12: Neoantigen Cancer Vaccine Market (Brain Cancer), $Million, 2023-2030
  • Figure 15.1: Global Neoantigen Cancer Vaccine Market Snapshot
  • Figure 15.2: Neoantigen Cancer Vaccine Market (by Region), $Million, 2023-2030
  • Figure 15.3: North America: Market Dynamics
  • Figure 15.4: North America Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 15.5: North America Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
  • Figure 15.6: Projections of the Older Adult Population in the U.S.: 2020 to 2060 (Million)
  • Figure 15.7: U.S. Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.8: Canada Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.9: Europe-Market Dynamics
  • Figure 15.10: Europe Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 15.11: Europe Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
  • Figure 15.12: Germany Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.13: France Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.14: U.K. Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.15: Italy Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.16: Spain Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.17: Rest-of-Europe Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.18: Asia-Pacific-Market Dynamics
  • Figure 15.19: Asia-Pacific Neoantigen Cancer Vaccine Market, $Million, 2023-2030
  • Figure 15.20: Asia-Pacific Neoantigen Cancer Vaccine Market (by Country), $Million, 2023 vs 2030
  • Figure 15.21: Japan Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.22: China Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.23: Australia Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.24: South Korea Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.25: Israel Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 15.26: Rest-of-Asia-Pacific Neoantigen Cancer Vaccine Market, 2023-2030
  • Figure 16.1: Moderna Therapeutics: Technology and Capabilities
  • Figure 16.2: Moderna Therapeutics: Therapeutic Focus Segmentation
  • Figure 16.3: Moderna Therapeutics: Overall Financials, 2016-2018
  • Figure 16.4: Moderna Therapeutics.: R&D Expenditure, 2016-2018
  • Figure 16.5: Moderna Therapeutics: SWOT Analysis
  • Figure 16.6: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 16.7: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 16.8: F. Hoffmann-La Roche Ltd: Revenue, by Segment, 2016-2018
  • Figure 16.9: F. Hoffmann-La Roche Ltd: Revenue Split for Pharmaceuticals, 2016-2018
  • Figure 16.10: F. Hoffmann-La Roche Ltd: Revenue, by Region, 2016-2018
  • Figure 16.11: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 16.12: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 16.13: AstraZeneca plc: Therapeutic Segmentation Focus
  • Figure 16.14: AstraZeneca plc: Overall Financials, 2016-2018
  • Figure 16.15: AstraZeneca plc: Net Revenue, by Region, 2016-2018
  • Figure 16.16: AstraZeneca plc: R&D Expense, 2016-2018
  • Figure 16.17: AstraZeneca: SWOT Analysis
  • Figure 16.18: Agenus: Technology and Capabilities (as per type of product)
  • Figure 16.19: Agenus: Therapeutic Focus Segmentation
  • Figure 16.20: Agenus: Overall Financials, 2016-2018
  • Figure 16.21: Agenus: R&D Expenditure, 2016-2018
  • Figure 16.22: Agenus: SWOT Analysis
  • Figure 16.23: OSE Immunotherapeutics: Therapeutic Focus Segmentation
  • Figure 16.24: OSE Immunotherapeutics: Overall Financials, 2016-2018
  • Figure 16.25: OSE Immunotherapeutics: R&D Expenditure, 2016-2018
  • Figure 16.26: OSE Immunotherapeutics: SWOT Analysis
  • Figure 16.27: Advaxis: Therapeutic Focus Segmentation
  • Figure 16.28: Advaxis: Overall Financials, 2016-2018
  • Figure 16.29: Advaxis: R&D Expenditure, 2016-2018
  • Figure 16.30: Advaxis: SWOT Analysis
  • Figure 16.31: Medigene: Therapeutic Segmentation Focus
  • Figure 16.32: Medigene: Overall Financials, 2016-2018
  • Figure 16.33: Medigene: R&D Expenditure, 2016-2018
  • Figure 16.34: Medigene, Inc.: SWOT Analysis
  • Figure 16.35: Neon Therapeutics: Therapeutic Segmentation Focus (Available from FY2019)
  • Figure 16.36: Neon Therapeutics: R&D Expenditure, 2016-2018
  • Figure 16.37: Neon Therapeutics: SWOT Analysis
  • Figure 16.38: Genocea Corporation: Therapeutic Focus Segmentation
  • Figure 16.39: Genocea Biosciences: SWOT Analysis
  • Figure 16.40: Immunovative Therapies: SWOT Analysis
  • Figure 16.41: Gritstone Oncology: Therapeutic Segmentation Focus
  • Figure 16.42: Gritstone Oncology: SWOT Analysis
  • Figure 16.43: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)
  • Figure 16.44: Nouscom: SWOT Analysis
  • Figure 16.45: NantBioScience: SWOT Analysis
  • Figure 16.46: Immunovaccine: SWOT Analysis
  • Figure 16.47: BioLineRx: SWOT Analysis
目次
Product Code: BH181A

"Global Neoantigen Cancer Vaccine Market is Projected to Reach $1826.1 Million by 2030."

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccine market?
  • What are the underlying structures resulting in the emerging trends within the global neoantigen cancer vaccine market?
  • How is each segment expected to grow in the global neoantigen cancer vaccine market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2030?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the expected key regulatory implications in the developed and developing regions for the neoantigen cancer vaccines?
  • Who are the leading players with significant offerings to the global neoantigen cancer vaccine market? What is the expected market dominance for each of these leading players?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2023-2030?
  • What are the key applications in global neoantigen cancer vaccine market? What are the major segments of these applications?
  • Which are the dominant disease types to which the global neoantigen cancer vaccine market caters? Which oncology specialty is expected to hold the maximum market share during the forecast period (2023-2030) ?
  • What is the scope of the global neoantigen cancer vaccine market in North America, Europe, Asia-Pacific, and Rest-of-the-World?

Global Neoantigen Cancer Vaccine Market Forecast, 2023-2030

The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030. The neoantigen cancer vaccine market is expected to generate $227.1 million revenue in 2023, owing to the expected launch of first neoantigen vaccine Tedopi in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to the major drivers in this market such as rising prevalence of cancers, increase in adoption of personalized medicine to tailor patient's treatment on an individual level, and significant external funding for executing research and development exercise. However, there are significant challenges which are restraining the market growth. These challenges include expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Expert Quote

"The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The Cost and time to manufacture have come down in the last four years and as technology improves it will come down more."

Scope of the Market Intelligence on Neoantigen Cancer Vaccine Market

The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market and current clinical landscape.

The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.

Market Segmentation

  • The neoantigen cancer vaccine market (on the basis of approach) is further segmented into personalized and off-the-shelf neovaccines.
  • The neoantigen cancer vaccine market (on the basis of disease/application) is segmented into hematological malignancies, gynecological cancer, urinary system cancer, melanoma, breast cancer, gastrointestinal cancer, lung cancer, solid tumor, prostate, head and neck, and brain cancer.
  • The neoantigen cancer vaccine market (on the basis of neovaccine type) is segmented into RNA vaccine, peptide vaccine, dendritic cell vaccine, lipid vaccine, and yeast-based vaccine.
  • The neoantigen cancer vaccine market (on the basis of line of therapy) is segmented into first, second and later lines therapy.
  • The neoantigen cancer vaccine market (on the basis of therapy type) is segmented into mono/combination approaches.
  • The neoantigen cancer vaccine market (on the basis of ROA) is segmented into intradermal, subcutaneous, and intramuscular administrations.

Pipeline Segmentation

  • The emerging neoantigen cancer vaccines are segmented (on the basis of approach) into personalized and off-the-shelf neovaccines.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of disease/application) into hematological malignancies, gynecological cancer, urinary system cancers, melanoma, breast cancer, gastrointestinal cancers, lung cancers, solid tumors, prostate, head and neck, and brain cancer.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of neovaccine type) into RNA vaccine, peptide vaccine, dendritic cell vaccine, lipid vaccine, and yeast-based vaccine.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of neovaccine delivery vehicle) into lipid-based, protein-based delivery, viral, bacteria-based delivery approaches.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of line of therapy) into first, second, and later lines therapy.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of product type) into self-originator and in-licensed products.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of developmental phase) into Phase I, II, and III.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of therapy type) into mono/combination approaches.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of ROA) into intradermal, subcutaneous, and intramuscular administrations.
  • The emerging neoantigen cancer vaccines are segmented (on the basis of vaccination type) into preventive and therapeutic neovaccines.

Key Companies in the Neoantigen cancer vaccine Market

The key manufacturers who have been contributing significantly to the neoantigen cancer vaccine market include Roche, Medimmune, Moderna Therapeutics/Merck (in 50-50 Joint venture), Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, Vaccibody, Brightpath Biotherapeutics, Geneos Therapeutics, among others.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Data Sources
    • 3.1.1 Primary Data Sources
    • 3.1.2 Secondary Data Sources
  • 3.2 Market Estimation Model
    • 3.2.1 Considered Factors for Data Prediction and Modeling
    • 3.2.2 Assumptions and Limitations

4 Neoantigen Vaccines in Cancer Immunotherapy: Overview

  • 4.1 Introduction
  • 4.2 Cancer Antigens
  • 4.3 Targeting Cancer Neoantigen: A next wave of innovation in Oncology?
  • 4.4 Neoantigen Cancer Vaccine Mechanism of Action
  • 4.5 Types of Neoantigen Cancer Vaccines, by Product Type
    • 4.5.1 Personalized neoantigens vaccines
    • 4.5.2 Off-the-shelf Neoantigen vaccines
  • 4.6 Types of Neoantigen Cancer Vaccine Market, by Neovaccine Types (Biological Platform)
    • 4.6.1 Nucleic acid/DNA/mRNA Vaccines
    • 4.6.2 Peptide Vaccines
    • 4.6.3 Dendritic Cell-based Vaccines
  • 4.7 Types of Neoantigen Cancer Vaccine, by Delivery Strategies
    • 4.7.1 Lipid-Based Approaches
    • 4.7.2 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant
    • 4.7.3 Sequential immunization of Viral Prime and RNA Boost
    • 4.7.4 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes
    • 4.7.5 Other Approaches
  • 4.8 Prediction Software for Neoantigens
    • 4.8.1 Limitations of Neoantigen Prediction Process
  • 4.9 Limitations of Neoantigen Cancer Vaccines
    • 4.9.1 Lower Tumor Mutational Burden
    • 4.9.2 Neoantigens Maturity
  • 4.10 Future Prospects
    • 4.10.1 Multi-Epitope Vaccination
    • 4.10.2 Combination with Other Kinds of Immunotherapies and Conventional Treatments
    • 4.10.3 Combination with Traditional Cancer Therapies

5 Legal Requirements and Regulations

  • 5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccines
    • 5.1.1 U.S. FDA Guidelines for BLA Submission
    • 5.1.2 EMA Biologics License Application Process
      • 5.1.2.1 Centralized Procedure
      • 5.1.2.2 Decentralized Procedure
      • 5.1.2.3 Mutual-Recognition Procedure
  • 5.2 Regulatory Challenges
  • 5.3 Successful Regulatory Strategies

6 Market Landscape

  • 6.1 Growth Share Analysis
    • 6.1.1 Growth Share Matrix by Oncology Specialty
    • 6.1.2 Growth Share Matrix by Product Type
    • 6.1.3 Growth Share Matrix by Region
    • 6.1.4 Growth Share Matrix by Line of Therapy
    • 6.1.5 Growth Share Matrix by Type of Therapy
    • 6.1.6 Growth Share Matrix by Type of Neovaccine
  • 6.2 FDA Review Landscape
  • 6.3 Patent Landscape

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Emerging and Current Market Trends
  • 7.3 Market Drivers
    • 7.3.1 Increasing Global Prevalence of Cancers
    • 7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
    • 7.3.3 Significant External Funding for Executing Research and Development Exercise
  • 7.4 Market Restraints
    • 7.4.1 Higher Cost of Personalized Cancer Vaccines
    • 7.4.2 Hurdles in Clinical Development and Optimization Process
    • 7.4.3 Uncertain Reimbursement Scenario
    • 7.4.4 Payer Uncertainty and Outcome-Based Pricing
    • 7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
  • 7.5 Market Opportunities
    • 7.5.1 Treatment Gaps
    • 7.5.2 Reduced Turnaround Time and Cost
    • 7.5.3 Partnerships and Collaboration Between Various Healthcare Stakeholders
    • 7.5.4 Data Analytics

8 Pipeline Landscape

  • 8.1 Emerging Neoantigen Vaccines
  • 8.2 Clinical Trials Heat Map
  • 8.3 Pipeline Analysis
    • 8.3.1 By Phase of Development
    • 8.3.2 By Type of Therapy
    • 8.3.3 By Product Type
    • 8.3.4 By Treatment Strategy
    • 8.3.5 By Type of Neovaccine
    • 8.3.6 By Delivery Approach
    • 8.3.7 By Line of Therapy
    • 8.3.8 By Oncology Specialty
    • 8.3.9 By Route of Administration
    • 8.3.10 By Core Product Status
    • 8.3.11 By Neoantigen Payload

9 Competitive Landscape

  • 9.1 Key Strategies and Developments
    • 9.1.1 Synergistic Activities
    • 9.1.2 Funding and Expansion Activities
    • 9.1.3 Mergers and Acquisitions
  • 9.2 Partnership and Financing Opportunities

10 Global Neoantigen Cancer Vaccine Market by Product Type, 2023-2030

  • 10.1 Personalized Neoantigen Vaccines
  • 10.2 Off-the-Shelf Neoantigen Vaccines

11 Global Neoantigen Cancer Vaccine Market by Type of Neovaccine, 2023-2030

  • 11.1 Nucleic Acid/DNA/mRNA Vaccines
    • 11.1.1 DNA Vaccines
  • 11.2 RNA Vaccines
  • 11.3 Peptide Vaccines
  • 11.4 Dendritic Cell-Based Vaccines

12 Global Neoantigen Cancer Vaccine Market by Line of Therapy, 2023-2030

  • 12.1 First Line Neovaccines Regimens
  • 12.2 Second Line Neovaccine Regimens
  • 12.3 Later Lines Neovaccines Regimens

13 Global Neoantigen Cancer Vaccine Market by Therapy Type, 2023-2030

  • 13.1 Mono Therapeutic Regimens
  • 13.2 Combinatorial Regimens

14 Global Neoantigen Cancer Vaccine Market by Therapeutic Specialty, 2023-2030

  • 14.1 Hematological Malignancies
  • 14.2 Melanoma
  • 14.3 Breast Cancer
  • 14.4 Gastrointestinal Cancer
  • 14.5 Lung Cancer
  • 14.6 Solid Tumors
  • 14.7 Urinary System Cancer
  • 14.8 Prostate Cancer
  • 14.9 Head and Neck Cancers
  • 14.10 Gynecologic Cancers
  • 14.11 Brain Cancer

15 Global Neoantigen Cancer Vaccine Market by Region, 2023-2030

  • 15.1 Overview
  • 15.2 North America
    • 15.2.1 Market Size and Forecast
    • 15.2.2 Key Developments
  • 15.3 Canada
    • 15.3.1 Market Size and Forecast
    • 15.3.2 Key Developments
  • 15.4 Europe
    • 15.4.1 Germany
      • 15.4.1.1 Market Size and Forecast
      • 15.4.1.2 Key Developments
    • 15.4.2 France
      • 15.4.2.1 Market Size and Forecast
      • 15.4.2.2 Key Developments
    • 15.4.3 U.K.
      • 15.4.3.1 Market Size and Forecast
      • 15.4.3.2 Key Developments
    • 15.4.4 Italy
      • 15.4.4.1 Market Size and Forecast
    • 15.4.5 Spain
      • 15.4.5.1 Market Size and Forecast
    • 15.4.6 Rest-of-Europe
      • 15.4.6.1 Market Size and Forecast
      • 15.4.6.2 Key developments
  • 15.5 Asia-Pacific
    • 15.5.1 Japan
      • 15.5.1.1 Market Size and Forecast
      • 15.5.1.2 Key Developments
    • 15.5.2 China
      • 15.5.2.1 Market Size and Forecast
      • 15.5.2.2 Key developments
    • 15.5.3 Australia
      • 15.5.3.1 Market Size and Forecast
    • 15.5.4 South Korea
      • 15.5.4.1 Market Size and Forecast
    • 15.5.5 Israel
      • 15.5.5.1 Market Size and Forecast
    • 15.5.6 Rest-of-Asia-Pacific
      • 15.5.6.1 Market Size and Forecast
      • 15.5.6.2 Key Developments

16 Company Profiles

  • 16.1 Moderna Therapeutics
    • 16.1.1 Company Overview
    • 16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market
    • 16.1.3 Technology and Capabilities
    • 16.1.4 Financials
    • 16.1.5 Key Insights About Financial Health of the Company
    • 16.1.6 SWOT Analysis: Moderna Therapeutics
  • 16.2 F. Hoffmann-La Roche Ltd
    • 16.2.1 Company Overview
    • 16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
    • 16.2.3 Technology and Capabilities
      • 16.2.3.1 Technology Platform
      • 16.2.3.2 Manufacturing
    • 16.2.4 Financials
    • 16.2.5 Key Insights About Financial Health of the Company
    • 16.2.6 SWOT Analysis: F. Hoffmann-La Roche
  • 16.3 AstraZeneca plc
    • 16.3.1 Company Overview
    • 16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
    • 16.3.3 Financials
    • 16.3.4 Key Insights About Financial Health of the Company
    • 16.3.5 SWOT Analysis: AstraZeneca
  • 16.4 Agenus
    • 16.4.1 Company Overview
    • 16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
    • 16.4.3 Technology and Capabilities
      • 16.4.3.1 Technology Platforms
      • 16.4.3.2 Manufacturing
      • 16.4.3.3 Adjuvant
    • 16.4.4 Financials
    • 16.4.5 Key Insights About Financial Health of the Company
    • 16.4.6 SWOT Analysis: Agenus
  • 16.5 OSE Immunotherapeutics
    • 16.5.1 Company Overview
    • 16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
    • 16.5.3 Technology and Capabilities
      • 16.5.3.1 Technology Platforms
      • 16.5.3.2 Manufacturing
    • 16.5.4 Financials
    • 16.5.5 Key Insights About Financial Health of the Company
    • 16.5.6 SWOT Analysis: OSE Immunotherapeutics
  • 16.6 Advaxis
    • 16.6.1 Company Overview
    • 16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
    • 16.6.3 Technology and Capabilities
      • 16.6.3.1 Technology platform
    • 16.6.4 Manufacturing
    • 16.6.5 Financials
    • 16.6.6 Key Insights About Financial Health of the Company
    • 16.6.7 SWOT Analysis: Advaxis
  • 16.7 Medigene
    • 16.7.1 Company Overview
    • 16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
    • 16.7.3 Technology and Capabilities
      • 16.7.3.1 Technology Platform
      • 16.7.3.2 Manufacturing
    • 16.7.4 Financials
    • 16.7.5 Key Insights About Financial Health of the Company
    • 16.7.6 SWOT Analysis: Medigene
  • 16.8 Neon Therapeutics
    • 16.8.1 Company Overview
    • 16.8.2 Role of Neon Therapeutics in the Global Neoantigen cancer Vaccine Market
    • 16.8.3 Technology and Capabilities
      • 16.8.3.1 Technology Platforms
    • 16.8.4 Manufacturing
    • 16.8.5 Key Insights About Financial Health of the Company
    • 16.8.6 SWOT Analysis: Neon Therapeutics
  • 16.9 Genocea Biosciences
    • 16.9.1 Company Overview
    • 16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
    • 16.9.3 Technology and Capabilities
      • 16.9.3.1 Technology Platform
      • 16.9.3.2 Manufacturing Capabilities
    • 16.9.4 SWOT Analysis: Genocea Biosciences
  • 16.10 Immunovative Therapies
    • 16.10.1 Company Overview
    • 16.10.2 Role of Immunovative Therapies in the Neoantigen Cancer Vaccine Market
    • 16.10.3 Technology and Capabilities
      • 16.10.3.1 Technology Platform
      • 16.10.3.2 Manufacturing
    • 16.10.4 SWOT Analysis: Immunovative Therapies
  • 16.11 Gritstone Oncology
    • 16.11.1 Company Overview
    • 16.11.2 Role of Gritstone Oncology in the Neoantigen Cancer Vaccine Market
    • 16.11.3 Technology and Capabilities
      • 16.11.3.1 Technology Platform
      • 16.11.3.2 Manufacturing
    • 16.11.4 SWOT Analysis: Gritstone Oncology
  • 16.12 Nouscom
    • 16.12.1 Company Overview
    • 16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
    • 16.12.3 Technology and Capabilities
      • 16.12.3.1 Technology Platform
      • 16.12.3.2 Manufacturing
    • 16.12.4 SWOT Analysis: Nouscom
  • 16.13 NantBioScience
    • 16.13.1 Company Overview
    • 16.13.2 Role of NantBioScience in the Neoantigen cancer vaccine Market
    • 16.13.3 SWOT Analysis: NantBioScience
  • 16.14 Immunovaccine
    • 16.14.1 Company Overview
    • 16.14.2 Role of Immunovaccine in the Neoantigen Cancer Vaccine Market
    • 16.14.3 SWOT Analysis: Immunovaccine
  • 16.15 BioLineRx
    • 16.15.1 Company Overview
    • 16.15.2 Role of BioLineRx in the Neoantigen Cancer Vaccine Market
    • 16.15.3 SWOT Analysis: BioLineRx

17 Anticipated Milestones

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.